Edgewise Therapeutics (EWTX) Competitors $14.84 -0.56 (-3.64%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$14.80 -0.04 (-0.28%) As of 04/25/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EWTX vs. TLX, BPMC, SRPT, AXSM, NUVL, VRNA, GRFS, KRYS, ADMA, and CYTKShould you be buying Edgewise Therapeutics stock or one of its competitors? The main competitors of Edgewise Therapeutics include Telix Pharmaceuticals Limited American Depositary Shares (TLX), Blueprint Medicines (BPMC), Sarepta Therapeutics (SRPT), Axsome Therapeutics (AXSM), Nuvalent (NUVL), Verona Pharma (VRNA), Grifols (GRFS), Krystal Biotech (KRYS), ADMA Biologics (ADMA), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry. Edgewise Therapeutics vs. Telix Pharmaceuticals Limited American Depositary Shares Blueprint Medicines Sarepta Therapeutics Axsome Therapeutics Nuvalent Verona Pharma Grifols Krystal Biotech ADMA Biologics Cytokinetics Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) and Edgewise Therapeutics (NASDAQ:EWTX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, community ranking, analyst recommendations, institutional ownership, media sentiment and dividends. Is TLX or EWTX more profitable? Telix Pharmaceuticals Limited American Depositary Shares' return on equity of 0.00% beat Edgewise Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Telix Pharmaceuticals Limited American Depositary SharesN/A N/A N/A Edgewise Therapeutics N/A -26.83%-25.67% Which has preferable valuation and earnings, TLX or EWTX? Telix Pharmaceuticals Limited American Depositary Shares has higher revenue and earnings than Edgewise Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTelix Pharmaceuticals Limited American Depositary Shares$783.21M8.11N/AN/AN/AEdgewise TherapeuticsN/AN/A-$100.16M-$1.45-10.23 Does the MarketBeat Community believe in TLX or EWTX? Edgewise Therapeutics received 35 more outperform votes than Telix Pharmaceuticals Limited American Depositary Shares when rated by MarketBeat users. However, 100.00% of users gave Telix Pharmaceuticals Limited American Depositary Shares an outperform vote while only 72.22% of users gave Edgewise Therapeutics an outperform vote. CompanyUnderperformOutperformTelix Pharmaceuticals Limited American Depositary SharesOutperform Votes4100.00% Underperform VotesNo VotesEdgewise TherapeuticsOutperform Votes3972.22% Underperform Votes1527.78% Do analysts rate TLX or EWTX? Telix Pharmaceuticals Limited American Depositary Shares presently has a consensus target price of $22.00, suggesting a potential upside of 17.02%. Edgewise Therapeutics has a consensus target price of $40.13, suggesting a potential upside of 170.38%. Given Edgewise Therapeutics' higher possible upside, analysts plainly believe Edgewise Therapeutics is more favorable than Telix Pharmaceuticals Limited American Depositary Shares.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telix Pharmaceuticals Limited American Depositary Shares 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Edgewise Therapeutics 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the media favor TLX or EWTX? In the previous week, Edgewise Therapeutics had 9 more articles in the media than Telix Pharmaceuticals Limited American Depositary Shares. MarketBeat recorded 12 mentions for Edgewise Therapeutics and 3 mentions for Telix Pharmaceuticals Limited American Depositary Shares. Edgewise Therapeutics' average media sentiment score of 1.10 beat Telix Pharmaceuticals Limited American Depositary Shares' score of 0.00 indicating that Edgewise Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals Limited American Depositary Shares 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Edgewise Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryTelix Pharmaceuticals Limited American Depositary Shares and Edgewise Therapeutics tied by winning 5 of the 10 factors compared between the two stocks. Get Edgewise Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EWTX vs. The Competition Export to ExcelMetricEdgewise TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.55B$6.68B$5.44B$7.80BDividend YieldN/A3.17%5.43%4.31%P/E Ratio-9.897.1422.1418.40Price / SalesN/A238.89389.70101.29Price / CashN/A65.6738.2034.62Price / Book3.286.266.664.18Net Income-$100.16M$142.48M$3.21B$247.71M7 Day Performance10.70%7.91%5.83%6.45%1 Month Performance-34.91%-6.03%-4.32%-3.14%1 Year Performance-6.90%-0.96%17.83%5.40% Edgewise Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EWTXEdgewise Therapeutics2.3769 of 5 stars$14.84-3.6%$40.13+170.4%-6.9%$1.61BN/A-9.8960Positive NewsGap DownTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.21-3.0%$22.00+35.7%N/A$5.48B$783.21M0.00N/ABPMCBlueprint Medicines2.5137 of 5 stars$84.18-0.6%$124.95+48.4%-3.4%$5.38B$508.82M-77.94640Upcoming EarningsNews CoveragePositive NewsSRPTSarepta Therapeutics4.6312 of 5 stars$55.23+2.7%$158.70+187.3%-52.6%$5.36B$1.90B44.18840AXSMAxsome Therapeutics4.5809 of 5 stars$103.00-1.4%$169.80+64.9%+48.6%$5.02B$385.69M-17.20380Positive NewsNUVLNuvalent1.8854 of 5 stars$69.95-2.4%$115.50+65.1%+11.2%$5.01BN/A-20.1640News CoveragePositive NewsVRNAVerona Pharma2.0615 of 5 stars$60.07+2.0%$75.43+25.6%+327.6%$4.85B$42.28M-31.2930Upcoming EarningsAnalyst RevisionNews CoveragePositive NewsGRFSGrifols3.237 of 5 stars$7.01-1.0%N/A+15.0%$4.82B$7.21B5.9926,300Gap UpKRYSKrystal Biotech4.7591 of 5 stars$161.91-4.0%$220.00+35.9%+8.0%$4.68B$290.52M54.15210News CoveragePositive NewsADMAADMA Biologics1.9478 of 5 stars$19.64-7.8%$22.50+14.6%+239.4%$4.64B$426.45M70.14530Positive NewsCYTKCytokinetics4.0132 of 5 stars$37.93-3.9%$81.63+115.2%-37.6%$4.52B$18.47M-7.05250Analyst Forecast Related Companies and Tools Related Companies Telix Pharmaceuticals Limited American Depositary Shares Competitors Blueprint Medicines Competitors Sarepta Therapeutics Competitors Axsome Therapeutics Competitors Nuvalent Competitors Verona Pharma Competitors Grifols Competitors Krystal Biotech Competitors ADMA Biologics Competitors Cytokinetics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EWTX) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edgewise Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edgewise Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
